



# Alabama Board of Nursing

## Cosmetic Botulinum Toxin Injection Protocol

**COSMETIC BOTULINUM TOXIN INJECTION PROTOCOL:** The CRNP scope of practice includes: evaluation of patients for treatment appropriateness with neuromodulators, development of individualized treatment plans including selection of the appropriate neuromodulator treatment product and dosage, administration by injection of an FDA approved, brand-name botulinum toxin A ("Botox"), prabotulinumtoxinA-xvfs ("Jeuveau"), incobotulinumtoxinA ("Xeomin"), abobotulinumtoxinA ("Dysport"), and daxibotulinumtoxinA-lanm ("Daxxify") for cosmetic purposes according to the treatment plan, follow up to evaluate treatment effectiveness with intervention as needed to correct adverse reactions, and to adjust the-treatment plan as clinically indicated.

### PHYSICIAN REQUIREMENTS:

The collaborating physician must be qualified under one of the following conditions:

1. Board certified by a board recognized by the American Board of Medical Specialties or the American Osteopathic Association in plastic surgery, facial plastic surgery, or dermatology.
2. Completed not less than eight (8) hours of training in the injection of cosmetic injectables, including the administration by injection of botulinum-toxin-A and its safety protocols, have actively practiced as an injector in Alabama or in another state for more than 12 months, and performed not less than 25 procedures [1 (one) set of injections equals 1 (one) procedure].

**APPLICATION LINK:** [Cosmetic Botulinum Toxin Injection Protocol Application](#)

**POPULATION FOCI EXCLUSIONS:** Neonatal, Pediatric/ Pediatric Acute, and Psychiatric-Mental Health CRNPs, and Certified Nurse- Midwives

### LIMITATIONS:

- The administration of botulinum toxins must occur in a medical setting, such as a hospital, ambulatory surgical center, or the private clinical office of a physician or CRNP. A private clinical office refers to an approved collaborative practice site where a physician and/or a CRNP practices medicine or advanced practice nursing, whether as an individual, in a group, a professional corporation, or a professional association practice. **The administration of botulinum toxins is prohibited in non-medical settings, including private residences and event venues. Such locations cannot be designated as a principal practice site.**
- The collaborating or covering physician (MD/DO) who meets the same qualifications as the collaborating physician must be physically available on site when the procedure is performed by the CRNP.
- No more than 100 units, or Botox unit equivalent, may be injected for cosmetic purposes within a 3-month period.
- No more than 400 units, or Botox unit equivalent, may be injected into a single patient within a 3-month period, in compliance with the FDA package insert, inclusive of all providers treating the patient and inclusive of treatment for migraines and hyperhidrosis.



# Alabama Board of Nursing

## Cosmetic Botulinum Toxin Injection Protocol

- The CRNP may purchase botulinum toxin with physician approval from an FDA approved manufacturer.
- Cosmetic botulinum toxin A shall be limited to FDA approved anatomical treatment areas.
- Injections of botulinum toxins are not to be performed on patients who are pregnant or breastfeeding, or patients with glaucoma.

### EDUCATION/ COURSE REQUIREMENTS:

- Prior to approval for performing injections, the CRNP will have received:
  1. **10 hours** of didactic training, which may include lectures and/or a course determined by the collaborating physician. Training must include: injectable safety; education on anatomical structures, such as nerves and blood vessels, which must be avoided when injecting neuromodulators; Board rules; and
  2. Successful completion of and certification from a course approved by the Board of Medical Examiners or the Board of Nursing. The course must consist of not less than four (4) hours of training and must not be completed exclusively through online or remote modalities. The curriculum must include in-person instruction and hands-on clinical training.
  3. Previous training in another state may be considered on a case-by-case basis to fulfill the required training.

### **Training Requirements for Skill(s) or Procedure(s)**

- The collaborating physician or covering physician is required to be physically present on site during the CRNP training for this procedure.
- The collaborating physician must evaluate the competency of the CRNP after completion of the certification and training before administering botulinum toxins. Maintenance of competency training and procedures must be documented and readily retrievable.

*Supervised practice must be submitted to the Board within one (1) year of approval to train, or the approval to train will lapse.*



# Alabama Board of Nursing Cosmetic Botulinum Toxin Injection Protocol

Skills/Procedures	Observation (if indicated)	Number Required for Initial	Annual Maintenance Requirement
<b>Cosmetic Botulinum Toxin Injection</b>  [1 (one) set of injections equals 1(one) procedure]	Observe <b>10</b> procedures	<b>50</b> procedures under the direct supervision of the collaborating or covering physician	No less than <b>25</b> procedures annually to maintain competency

**QUALITY ASSURANCE MONITORING REQUIRED:** Documented evaluation of the clinical practice (high risk/problem prone skill) against defined quality outcome measures, using a meaningful selected sample of patient records and a review of all adverse events [ABN Administrative Code § 610-X-5-.01(13)].

- All final procedures and reports will be logged for physician (MD/DO) review in accordance with established protocols and institutional policies.
- The results of the botulinum-toxin injections will be reviewed at least quarterly with the collaborating or covering physician and documented as part of the Quality Assurance Plan. Any adverse events will be recorded, included in all quality monitoring reviews, and reported to the site's designated safety officer. Examples of adverse events could include, but are not limited to, infection, ptosis, and arterial aneurysm. The collaborating/covering physician will intervene when indicated by this review and implement corrective action.

#### NOTES:

- Prior to providing the treatment, and annually thereafter, the CRNP must discuss with the collaborating physician any patient who is receiving a drug that potentially interferes with neuromuscular transmission and any patient who has pre-existing neuromuscular disorders. In addition, the treatment by the CRNP is contraindicated if the injection site is infected or if the patient has a hypersensitivity to Botox.
- Training may not begin until the CRNP receives written approval from the Alabama Board of Nursing, and the collaborating physician must receive written approval from the Alabama Board of Medical Examiners